Table 2.

Fully vaccinated persons (FVPs) and deaths averted due to routine immunisation activities over the years 2020–2030 for each disease and in total across all ten diseases (Haemophilus influenzae type b (Hib), hepatitis B (HepB), human papillomavirus (HPV), Japanese encephalitis (JE), measles, Neisseria meningitidis serogroup A (MenA), rotavirus (Rota), rubella, Streptococcus pneumoniae (PCV) and yellow fever (YF)). Relative change (%) in FVPs and deaths averted in comparison to the no-COVID-19 scenario also shown where relative change is given by 100*(COVID-19 scenario - no-COVID-19 scenario)/no-COVID-19 scenario. See Fig. 1 for more detail on the coverage scenarios.

Coverage scenario	Disease	FVPs in millions (Relative change (%))	Deaths averted in millions (Relative change (%))
No-COVID-19 2020: VIMC 2021–2029: Linear interpolation 2030: IA2030	HepB	1890.67	12.55
	Hib	1037.56	2.45
	HPV	322.28	3.84
	JE	261.37	0.12
	Measles	2111.43	19.32
	MenA	225.48	0.19
	PCV	917.14	2.10
	Rota	853.42	0.66
	Rubella	2014.30	0.65
	YF	243.99	1.84
	Total	9877.65	43.72
COVID-19 + default return 2020: VIMC – 10% 2021–2029: Linear interpolation 2030: IA2030 – 10%	HepB	1683.16 (-10.98)	11.14 (-11.21)
	Hib	923.25 (-11.02)	2.16 (-11.73)
	HPV	299.37 (-7.11)	3.55 (-7.50)
	JE	216.20 (-17.28)	0.10 (-15.61)
	Measles	1876.60 (-11.12)	17.03 (-11.86)
	MenA	190.44 (-15.54)	0.16 (-15.03)
	PCV	792.56 (-13.58)	1.83 (-13.16)
	Rota	759.96 (-10.95)	0.59 (-10.98)
	Rubella	1811.87 (-10.05)	0.59 (-9.93)
	YF	211.70 (-13.23)	1.61 (-12.33)
	Total	8765.12 (-11.26)	38.76 (-11.34)
COVID-19 + IA2030 return 2020: VIMC – 10% 2021–2029: Linear interpolation 2030: IA2030	HepB	1795.86 (-5.02)	11.86 (-5.49)
	Hib	984.18 (-5.14)	2.31 (-5.66)
	HPV	321.13 (-0.36)	3.82 (-0.70)
	JE	243.78 (-6.73)	0.12 (-5.99)
	Measles	1999.97 (-5.28)	18.21 (-5.73)
	MenA	208.50 (-7.53)	0.17 (-7.30)
	PCV	855.04 (-6.77)	1.97 (-6.48)
	Rota	817.68 (-4.19)	0.64 (-3.93)
	Rubella	1926.59 (-4.35)	0.63 (-4.25)
	YF	230.46 (-5.55)	1.73 (-5.82)
	Total	9383.19 (-5)	41.44 (-5.22)